Entyvio
Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis
May 11, 2020Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis
The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …
Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease
February 17, 2020Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …
Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis
September 27, 2019Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis
Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …
Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease
July 23, 2019Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …
Takeda scores Japanese Entyvio approval in Crohn’s disease
May 22, 2019Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma
Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show
May 20, 2019Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis
Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …
Takeda’s Entyvio secures Japanese approval in ulcerative colitis
July 2, 2018Sales and Marketing Entyvio, Japan, Takeda, pharma, ulcerative colitis
Takeda Pharmaceutical has announced that its monoclonal antibody, Entyvio (vedolizumab), has been approved for the treatment of patients with moderately …
Takeda presents long-term Entyvio data in CD and UC
March 21, 2016Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis
Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …
NICE u-turns on Entyvio for Crohn’s disease
July 10, 2015Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding
NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …
NICE rejects Takeda Crohn’s disease drug
December 23, 2014Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab
Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …
Latest content
